z-logo
Premium
Increased risk of central venous catheter–associated thrombosis in acute promyelocytic leukemia: a single‐institution experience
Author(s) -
Grisariu Sigal,
Spectre Galia,
Kalish Yosef,
Gatt Moshe E.
Publication year - 2013
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12087
Subject(s) - medicine , acute promyelocytic leukemia , thrombosis , myeloid leukemia , acute leukemia , central venous catheter , venous thrombosis , complication , leukemia , low molecular weight heparin , incidence (geometry) , induction chemotherapy , surgery , chemotherapy , catheter , biochemistry , retinoic acid , chemistry , physics , optics , gene
Background Patients with acute leukemia and in particular, acute promyelocytic leukemia ( APL ), are felt to be at high risk for developing venous thromboembolism. The presence of central venous catheters ( CVCs ) increases this risk; however, reports have varied regarding the frequency of this complication. Current guidelines do not recommend the routine use of prophylactic anticoagulation for patients with CVC . Methods We suspected an increased incidence of CVC thrombosis in patients with APL and therefore conducted a retrospective survey of 473 patients who were treated for acute leukemia at our institution. Results The overall rate of symptomatic CVC thrombosis was 6.8%. We found a significantly ( P  < 0.001) increased rate of symptomatic CVC thrombosis (32%) in patients with APL as compared with patients with acute lymphocytic leukemia and acute myeloid leukemia (6.4% and 4%, respectively). CVC thrombosis was most prevalent following induction treatment and was associated with higher platelet counts in patients with APL . Following this observation, 13 additional newly diagnosed patients with APL were treated with low molecular weight heparin prophylaxis during the recovery phase after chemotherapy. None had a thrombotic event. Conclusions Although our treatment group was small, we suggest considering prophylaxis for CVC thrombosis during platelet recovery after induction treatment in patients with APL .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom